Top Tweets for #COMy23
We had a lovely interview with Paola Neri (@UCalgary) at #COMy23 on the role of the bone marrow microenvironment in myeloma disease progression. Check it out below:
🎥 https://t.co/QyDieylTc8
@COMyCongress #MMsm #HemOnc
Check out our interview with @BrunoPaiva_UNAV from #COMy23, who discussed technical tips for accurate MRD assessment in multiple myeloma:
👉 https://t.co/79BcL5KQo3 👈
@COMyCongress #MMsm #mmMRD
Cellular therapies have transformed the myeloma treatment landscape over the years.
Tune in to our interview with @H_Einsele (@Uniklinikum_Wue), who discusses the current shift from alloSCT to immune therapies in this disease:
🎥 https://t.co/dNJ1JD6zjj
#MMsm #COMy23 #NCRM23
We had a lovely interview with Michel Delforge (@UZLeuven), who discussed the role of proteasome inhibitors in the treatment of R/R myeloma at #COMy23:
🎥 https://t.co/8A7YU19uvG
@COMyCongress #MMsm #HemOnc
#COMy23 | @JoshuaRichterMD of @IcahnMountSinai shares some insights into the efficacy of linvoseltamab in the treatment of R/R multiple myeloma. Find out more below:
🎥 https://t.co/fO9R3z1tjZ
@COMyCongress #MMsm #ImmunoOnc #HemOnc
#COMy23 | Enrique Ocio (@OcioEnrique) discusses major challenges with treating patients with triple-class refractory myeloma, highlighting the need for novel agents:
🎥 https://t.co/w8GJEWsoRN
@COMyCongress #MMsm #HemOnc
Find out more about the biology of high-risk multiple myeloma & advances being made in this space in our interview with @DrGarethMorgan1 (@nyulangone), filmed at #COMy23:
🎥 https://t.co/jNWsm9mp9E
@COMyCongress #MMsm #HemOnc
We had a lovely time in Paris speaking with experts at #COMy23 - thank you to all those who interviewed with us and to the organizers of this year's meeting for having us onsite!
To watch our interviews, visit:
🎥 https://t.co/qvCNqhqSJr
#MMsm #HemOnc @Mohty_EBMT
#COMy23 | @DrRakeshPopat shares some insights into the importance of ADCs in multiple myeloma and future considerations for these agents:
👉https://t.co/EITXKdxuYZ👈
@COMyCongress #MMsm #HemOnc #ImmunoOnc
Thank you all for making the success of @COMyCongress It is such a privilege to see the incredible advances achieved in myeloma. @TheIACH is committed to disseminate knowledge and educate without borders. The words of the GIANT Dr Merlini mean a lot to me. #comy23
Thank you for being with us and for your enthusiasm. It’s such a privilege to unite the whole myeloma family during the @COMyCongress #comy23
Thank you @COMyCongress!! Every evening I ventured for a walk. Here are some of my favorite memories
CONGRESS | #COMy23 | Cyrille Touzeau, @CHUNantes provided the updated phase IB study results of the MajesTEC-2 study assessing teclistamab combined with SC dara and lena in RRMM; promising clinical activity was observed (ORR: 93.5% and rapid time to first response: 1 month) #mmsm
CONGRESS | #COMy23 | @mvmateos presented the phase 1/2 MonumenTAL-1 results on talquetamab in heavily pre-treated patients with RRMM, demonstrating an ORR of >70%, median DOR:≥ 9 months, and a manageable safety profile overall #myeloma #mmsm #medicalcongress
CONGRESS | #COMy23 | Philippe Moreau, @CHUnantes shared some correlative analyses on teclistamab for patients with RRMM (MAJESTEC-1 study) which highlighted the importance of the baseline immune profile on clinical responses #mmsm #myeloma #medicalcongress
CONGRESS | #COMy23 | @paurotero shared updated 18-month follow-up data on ‘cohort C’ from the CARTITUDE-2 trial. Cilta-cel showed a clinical benefit in pts with heavily pre-treated RRMM and prior exposure to anti-BCMA therapy. ORR:60% in full cohort and MRD negativity: 70% #mmsm
CONGRESS | #COMy23 | Pieter Sonneveld, @ErasmusMC presented the 18-month follow-up data on 'cohort B' of the CARTITUDE-2 study assessing cilta-cel in patients with early relapse, ≤ 12 months after prior therapy. ORR:100% with 90% achieving CR; safety profile was manageable
#mmsm
CONGRESS | #COMy23 | @YimerHabte shared updated subgroup analyses by age and frailty from the full US MM-6 study on transitioning from bortezomib-based induction to IRd in patients with NDMM; demonstrating an improved depth of response and tolerable safety profile overall #mmsm
CONGRESS | #COMy23 | @JoshuaRichterMD,
@MountSinaiNYC presented clinical data on the phase 1/2 first in-human study on linvoseltamab for RRMM. At recommended dose of 200mg, ORR was 64%. MRD negativity rate of 60% seen in phase 2 and a manageable safety profile overall #myeloma
CONGRESS | #COMy23 | Ajay K. Nooka, @WinshipAtEmory presented 3-year follow up results from the phase II DREAMM-2 study assessing belantamab mafodotin for RRMM. Clinically meaningful responses were observed with no new safety signals compared to earlier analyses #mmsm #myeloma
Last Seen Hashtags on Sotwe
sofiacurly
Seen from Russia
rafitagoooool
Seen from United States
madmaxkarting
Seen from United States
incestoconmamá
Seen from Netherlands
minichat filter:videos since:2022-09-19
Seen from Turkey
selfpleasuresunday
Seen from Switzerland
ipcam()******* filter:native_video()
minichat
Seen from Germany
minichat anxiouspanda filter:native_video
Seen from United States
porn
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
118.9M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90.1M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers